73 related articles for article (PubMed ID: 7908691)
1. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil.
Linn SC; van Kalken CK; van Tellingen O; van der Valk P; van Groeningen CJ; Kuiper CM; Pinedo HM; Giaccone G
J Clin Oncol; 1994 Apr; 12(4):812-9. PubMed ID: 7908691
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List AF; Spier C; Greer J; Wolff S; Hutter J; Dorr R; Salmon S; Futscher B; Baier M; Dalton W
J Clin Oncol; 1993 Sep; 11(9):1652-60. PubMed ID: 8102639
[TBL] [Abstract][Full Text] [Related]
3. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
Trump DL; Smith DC; Ellis PG; Rogers MP; Schold SC; Winer EP; Panella TJ; Jordan VC; Fine RL
J Natl Cancer Inst; 1992 Dec; 84(23):1811-6. PubMed ID: 1359155
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
[TBL] [Abstract][Full Text] [Related]
5. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Sonneveld P; Schoester M; de Leeuw K
J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
[TBL] [Abstract][Full Text] [Related]
6. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
Chaudhary PM; Roninson IB
J Natl Cancer Inst; 1993 Apr; 85(8):632-9. PubMed ID: 8096875
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.
Speicher LA; Barone LR; Chapman AE; Hudes GR; Laing N; Smith CD; Tew KD
J Natl Cancer Inst; 1994 May; 86(9):688-94. PubMed ID: 7908988
[TBL] [Abstract][Full Text] [Related]
8. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients.
van Kalken CK; van der Hoeven JJ; de Jong J; Giaccone G; Schuurhuis GJ; Maessen PA; Blokhuis WM; van der Vijgh WJ; Pinedo HM
Eur J Cancer; 1991; 27(6):739-44. PubMed ID: 1829915
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Motzer RJ; Lyn P; Fischer P; Lianes P; Ngo RL; Cordon-Cardo C; O'Brien JP
J Clin Oncol; 1995 Aug; 13(8):1958-65. PubMed ID: 7636536
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.
Bates SE; Meadows B; Goldspiel BR; Denicoff A; Le TB; Tucker E; Steinberg SM; Elwood LJ
Cancer Chemother Pharmacol; 1995; 35(6):457-63. PubMed ID: 7882454
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
13. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
Barthomeuf C; Demeule M; Grassi J; Saidkhodjaev A; Beliveau R
Planta Med; 2006 Jun; 72(7):634-9. PubMed ID: 16739070
[TBL] [Abstract][Full Text] [Related]
14. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
Mickisch GH; Merlino GT; Aiken PM; Gottesman MM; Pastan I
J Urol; 1991 Aug; 146(2):447-53. PubMed ID: 1677434
[TBL] [Abstract][Full Text] [Related]
15. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
16. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
17. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents.
Hait WN; Choudhury S; Srimatkandada S; Murren JR
J Clin Invest; 1993 May; 91(5):2207-15. PubMed ID: 8098047
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
20. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
